Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222280 · ClinicalTrials.gov registry record · NA
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
A NA study of Alzheimer Disease and Alzheimer Dementia, sponsored by Covenant Health, US.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT07222280 is a NA study of Alzheimer Disease and Alzheimer Dementia that is actively recruiting participants, run by Covenant Health, US. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT07222280, a NA study of Alzheimer Disease and Alzheimer Dementia, is actively recruiting participants, sponsored by Covenant Health, US.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Quest AD-Detect blood test
Study Locations (6)
Tennessee
- Cumberland Medical Center - Crossville
- Roane Medical Center - Harriman
- Fort Sanders Regional Medical Center - Knoxville
- Fort Loudon Medical Center - Lenoir City
- Methodist Medical Center - Oak Ridge
- LeConte Medical Center - Sevierville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222280
The ClinicalTrials.gov registry entry for NCT07222280 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Covenant Health, US, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Quest AD-Detect blood test is the first listed.
NCT07222280 reports 6 study locations spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07222280 about?
NCT07222280 is a clinical study titled "Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy". The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the abilit...
What is the current status of trial NCT07222280?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-10. Estimated completion is 2026-03-31.
What conditions does trial NCT07222280 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Dementia, Encephalopathy, Delirium Confusional State, Cognitive Abnormality.
What interventions are being tested in trial NCT07222280?
The interventions under investigation include: Quest AD-Detect blood test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07222280?
This trial is sponsored by Covenant Health, US, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222280 being conducted?
This trial has 6 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.